Jakarta, February 16th, 2023 - Kimia Farma Sungwun Pharmacopia ("KFSP"), a subsidiary of PT Kimia Farma Tbk received an award as a pharmaceutical industry that actively participates in realizing the independence of national drug raw materials. The award was presented directly by the Head of the National Food and Drug Agency (BPOM), Penny K. Lukito to the President Director of KFSP, Pamian Siregar. This event was also a commemoration of BPOM's 22nd anniversary, titled "Symphony Dedication for You Indonesia," in Jakarta on Wednesday, (15/02/2023).
President Director of PT Kimia Farma Tbk. David Utama said that Kimia Farma supports the government's program to achieve national pharmaceutical industry resilience. Through its subsidiary, KFSP develops Drug Raw Materials (BBO) in accordance with the priority of national needs. This is in line with the goal of reducing imports of domestic pharmaceutical raw materials.
"Through its innovation, Kimia Farma is expected to play a role in reducing the number of imports of BBO or Active Pharmaceutical Ingredients (API) in Indonesia, and can continue to optimize the use of domestic BBO," said David.
President Director of KFSP, Pamian Siregar said that in 2022 KFSP has successfully produced 13 BBO items namely simvastatin, atorvastatin, rosuvastatin, clopidogrel, entecavir, remdesivir, tenofovir, lamivudine, zidovudine, efavirenz, attapulgite, iodium povidone dan amlodipine.
"Kimia Farma's commitment in creating domestic medicinal raw material products is very high. This is in line with KFSP's production facilities that have obtained certificates for Good Manufacturing Practices of Active Medicinal Raw Materials from the Indonesian Food and Drug Agency (BPOM) and Halal certificates from the Halal Product Guarantee Agency (BPJPH) so that quality and competitive products are produced," Pamian added.